Solid Biosciences Entered into a Research Collaboration with Phlox Therapeutics to Develop New Therapies for Rare Cardiac Diseases
Shots:
- The companies collaborated to develop novel precision genetic therapies using Solid’ vector biology, manufacturing capabilities & drug development experience with Phlox’s deep expertise in genetic cardiomyopathies & RNA therapies
- Solid Biosciences’ focused on advancing a portfolio of neuromuscular & cardiac programs, incl. SGT-003 for Duchenne, AVB-202 for Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy & additional assets for cardiac diseases
- The collaboration will target a sev. form of genetic dilated cardiomyopathy. The Dutch Top Sector Life Sciences and Health, a group that encourages public-private research & development partnerships to develop healthcare products and services, will also contribute financially to the collaboration
Ref: Globenewswire | Image: Solid Biosciences
Related News:- Eli Lilly Expands its 2021 Agreement with ProQR Therapeutics for New Genetic Therapies
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
